Cabot Corporation
CBTCabot Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (2 weeks in). Underneath, the last four quarters read deteriorating — profit −20.0% year on year, and 152% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cabot Corporation trades at $82.0, in a confirmed uptrend and 2 weeks into that stage. That is +8.7% against its own 200-day average. It sits at 64% of a 52-week range of $61 to $93. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 2 of stage 2. At $82.0 it trades +8.7% versus its 200-day average and sits at 64% of its 52-week range ($61–$93).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +74% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Cabot Corporation trades at 23.2× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.2× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −10.4% against a +13.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +5.8%/yr price move, ~+0.0%/yr came from earnings growth and ~+5.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cabot Corporation reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +112.5% at its peak → −31.9% latest) while ROCE still reads 19.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −7.0% | −4.9% | — | — |
| Profit | −9.5% | +16.6% | — | — |
| EPS | −10.4% | +18.5% | — | — |
| Stock price | +13.8% | +5.8% | +8.7% | +5.4% |
4-Factor Sector Score
46.3/100 — rank 19 of 29 in Specialty Chemicals · 81% evidence confidence
Cabot Corporation scores 46.3 out of 100 against the 29 companies it is compared with in Specialty Chemicals, ranking 19. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 8.9 + 13.3 + 16.5 + 7.6 = 46.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cabot Corporation reported $0.9 B of revenue in the Mar 26 quarter, −4.3% year on year. Over 4 years it has compounded at 2.1% a year. The last full year, FY25, came in at $3.7 B. The last four reported quarters add to $3.6 B.
FY25 revenue came in at $3.7 B (−7.0% on the year), capping 4 years at 2.1% compound. The latest quarter (Mar 26) printed $0.9 B, −4.3% year on year.
Pace check: the last four quarters averaged −8.7% growth against the decade's 2.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −8.7% over the last 4 quarters against −4.4%/yr over the last 8 — rolling over; TTM profit −31.9% vs −20.0%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cabot Corporation's operating margin is 14.4% in the Mar 26 quarter, −2.6 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 9.0% to 16.7%. The current quarter sits inside that band.
The latest quarter's operating margin is 14.4%, −2.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 9.0%–16.7%, and FY25's 16.7% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −2.6 pp year on year while gross margin went −2.2 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cabot Corporation earned $0.1 B of net profit in the Mar 26 quarter, −20.0% year on year. Full-year FY25 profit was $0.4 B. The 4-year compound rate is 7.0%. That is 8.9% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, −20.0% year on year. On the full year, FY25 printed $0.4 B (−9.5%), and the 4-year compound rate is 7.0%.
🚨 Why profit moved: revenue contributed −4.3% and the margin −2.6 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −28.8% vs revenue −8.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 152% of Cabot Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.7 B of operating cash against $0.4 B of profit. After $0.3 B of capital spending, $0.4 B was left as free cash.
FY25: operating cash of $0.7 B against reported profit of $0.4 B, leaving free cash of $0.4 B after $0.3 B of capital spending. Across the last 3 fiscal years the conversion rate is 152% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cabot Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 9.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $1.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Cabot Corporation earns a ROE of 253% in FY25. That is up from a trough of 185% in FY22. Return on invested capital clears the cost of that capital by +3.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.2% net margin on 0.97× asset turns.
FY25 ROE is 253%, recovered from a FY22 trough of 185% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 10.2% net margin × 0.97× asset turns × 25.40× balance-sheet leverage ≈ 251.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 11.0% − 7.5% = a +3.5 pp spread. The 7.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Cabot Corporation paid $1.80 per share over the last four reported quarters, up 4.7% on a year ago. The most recent declaration was $0.45 for Mar 26. Against the current price of $82.0 that is a trailing yield of 2.20%, measured on dividends already paid rather than on a forecast.
Cabot Corporation paid $1.80 per share across the last four reported quarters, most recently $0.45 for Mar 26. That is up 4.7% against the same quarter a year earlier. Against the current price of $82.0 the trailing twelve months work out to 2.20% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Cabot Corporation carries total debt of $1.3 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 10.83. On the annual view that ratio went from 8.29 in FY21 to 7.53 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $1.3 B against shareholder equity of $0.1 B — a debt-to-equity of 10.83. On the annual view, debt-to-equity went from 8.29 (FY21) to 7.53 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
6.8% of Cabot Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 6.8% of the float is sold short, and at typical trading volumes it would take about 5.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cabot Corporation: the Z-score reads 3.23. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.23 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.23.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1NewMarket CorporationNEU | 61.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.9/35 Revenue — · PAT — · OPM change -1.4 pp 45% evidence | 16.1/25 ROCE 5.5% · OPM 21.4% 76% evidence | 11.4/20 P/E 17× · PEG — 15% evidence | 17.5/20 RS sector 5.4% · RS bench 8.6% · 1Y 20.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 16.1 + 11.4 + 17.5 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Sociedad Química y Minera de Chile S.A.SQM | 61.7/100Mixed-positive evidence81% evidence | ASLEEP | 28.8/35 Revenue 18.3% · PAT 48.4% · OPM change 17.4 pp 83% evidence | 15.8/25 ROCE 6.3% · OPM 41% 76% evidence | 15.1/20 P/E 28.4× · PEG 0.81 65% evidence | 2.0/20 RS sector -9.7% · RS bench -8.3% · 1Y 62.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.8 + 15.8 + 15.1 + 2 = 61.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.7% and the one-year return is 62.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3WD-40 CompanyWDFC | 61.3/100Thin evidence · provisional58% evidence | TURNING | 21.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 17.4/25 ROCE 10.8% · OPM 16.3% 76% evidence | 10.2/20 P/E 30.4× · PEG — 15% evidence | 12.4/20 RS sector -3.7% · RS bench -1.4% · 1Y 7.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 17.4 + 10.2 + 12.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Sensient Technologies CorporationSXT | 60.7/100Thin evidence · provisional58% evidence | FADING | 20.4/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 12.8/25 ROCE 3.8% · OPM 15.3% 76% evidence | 9.8/20 P/E 33.2× · PEG — 15% evidence | 17.7/20 RS sector 7.9% · RS bench 10.5% · 1Y 9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 12.8 + 9.8 + 17.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Quaker Chemical CorporationKWR | 57.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.5/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 8.3/25 ROCE 1.7% · OPM 7% 76% evidence | 10.5/20 P/E 28.3× · PEG — 15% evidence | 17.2/20 RS sector 6% · RS bench 8.7% · 1Y 36.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8.3 + 10.5 + 17.2 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Axalta Coating Systems Ltd.AXTA | 56.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.3/35 Revenue — · PAT — · OPM change -2.3 pp 45% evidence | 11.7/25 ROCE 2.8% · OPM 11.6% 76% evidence | 10.8/20 P/E 21.1× · PEG — 15% evidence | 18.4/20 RS sector 6.4% · RS bench 9.2% · 1Y 32.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 18.4 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Ashland Inc.ASH | 54.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.8/35 Revenue — · PAT — · OPM change -2.5 pp 45% evidence | 7.0/25 ROCE 1% · OPM 8.1% 76% evidence | 8.9/20 P/E 57.8× · PEG — 15% evidence | 19.5/20 RS sector 10.3% · RS bench 12.9% · 1Y 39%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 7 + 8.9 + 19.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8The Sherwin-Williams CompanySHW | 53.8/100Thin evidence · provisional58% evidence | TURNING | 18.7/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence | 15.5/25 ROCE 7.1% · OPM 14.2% 76% evidence | 10.0/20 P/E 31.7× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench -4% · 1Y 2.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 15.5 + 10 + 9.6 = 53.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9H.B. Fuller CompanyFUL | 53.0/100Mixed-positive evidence85% evidence | BASING | 22.1/35 Revenue -0.6% · PAT 80.6% · OPM change 1.2 pp 95% evidence | 10.9/25 ROCE 2.6% · OPM 12.3% 76% evidence | 16.1/20 P/E 19× · PEG 0.5 65% evidence | 3.9/20 RS sector -14.3% · RS bench -12.2% · 1Y 4.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 10.9 + 16.1 + 3.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10International Flavors & Fragrances Inc.IFF | 52.4/100Mixed-positive evidence64% evidence | ASLEEP | 21.5/35 Revenue -5.6% · PAT — · OPM change 41.8 pp 62% evidence | 7.2/25 ROCE 1.2% · OPM 10% 76% evidence | 10.6/20 P/E 22.2× · PEG — 15% evidence | 13.1/20 RS sector 0% · RS bench 2.2% · 1Y 27.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 7.2 + 10.6 + 13.1 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Eastman Chemical CompanyEMN | 52.4/100Thin evidence · provisional58% evidence | ASLEEP | 18.6/35 Revenue — · PAT — · OPM change -4.6 pp 45% evidence | 13.3/25 ROCE 4.8% · OPM 8.6% 76% evidence | 11.2/20 P/E 17.4× · PEG — 15% evidence | 9.3/20 RS sector -5.5% · RS bench -3.5% · 1Y 19.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 13.3 + 11.2 + 9.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Avient CorporationAVNT | 52.2/100Mixed-positive evidence64% evidence | ASLEEP | 21.8/35 Revenue 1.3% · PAT 56.9% · OPM change 11.2 pp 62% evidence | 9.1/25 ROCE 1.9% · OPM 11.3% 76% evidence | 10.9/20 P/E 21.1× · PEG — 15% evidence | 10.4/20 RS sector -4.6% · RS bench -2.6% · 1Y 16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.1 + 10.9 + 10.4 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Balchem CorporationBCPC | 52.2/100Thin evidence · provisional58% evidence | TURNING | 18.6/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.6/25 ROCE 3.8% · OPM 20.5% 76% evidence | 9.9/20 P/E 33.2× · PEG — 15% evidence | 9.1/20 RS sector -5.8% · RS bench -3.6% · 1Y 9.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 14.6 + 9.9 + 9.1 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14RPM International Inc.RPM | 50.2/100Thin evidence · provisional58% evidence | TURNING | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 12.7/25 ROCE 4.8% · OPM 5% 76% evidence | 11.0/20 P/E 20.5× · PEG — 15% evidence | 8.2/20 RS sector -8.3% · RS bench -5.8% · 1Y -3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 12.7 + 11 + 8.2 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15PPG Industries, Inc.PPG | 50.2/100Thin evidence · provisional58% evidence | TURNING | 16.8/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence | 12.8/25 ROCE 3.6% · OPM 13.8% 76% evidence | 11.3/20 P/E 17.4× · PEG — 15% evidence | 9.3/20 RS sector -5.7% · RS bench -3.5% · 1Y 10.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 12.8 + 11.3 + 9.3 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Element Solutions IncESI | 49.8/100Thin evidence · provisional58% evidence | ASLEEP | 17.7/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 10.6/25 ROCE 2.3% · OPM 13.3% 76% evidence | 8.8/20 P/E 64.5× · PEG — 15% evidence | 12.7/20 RS sector 6.6% · RS bench 8.2% · 1Y 62.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 10.6 + 8.8 + 12.7 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Linde plcLIN | 47.5/100Thin evidence · provisional58% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence | 14.3/25 ROCE 3.6% · OPM 27.8% 76% evidence | 9.7/20 P/E 33.5× · PEG — 15% evidence | 4.7/20 RS sector -10.3% · RS bench -8.3% · 1Y 2.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.3 + 9.7 + 4.7 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Ecolab Inc.ECL | 46.7/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 12.9/25 ROCE 3.5% · OPM 15.3% 76% evidence | 9.5/20 P/E 37.4× · PEG — 15% evidence | 7.3/20 RS sector -9% · RS bench -6.6% · 1Y 3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 12.9 + 9.5 + 7.3 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Cabot Corporationthis pageCBT | 46.3/100Mixed-negative evidence81% evidence | ASLEEP | 8.9/35 Revenue -8.5% · PAT -31.2% · OPM change -3 pp 83% evidence | 13.3/25 ROCE 4.5% · OPM 14.3% 76% evidence | 16.5/20 P/E 14.2× · PEG 0.18 65% evidence | 7.6/20 RS sector -5.2% · RS bench -3.1% · 1Y 5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 13.3 + 16.5 + 7.6 = 46.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20Air Products and Chemicals, Inc.APD | 43.7/100Thin evidence · provisional58% evidence | BASING | 17.0/35 Revenue — · PAT — · OPM change 103.5 pp 45% evidence | 9.5/25 ROCE -5.8% · OPM 23.7% 76% evidence | 10.1/20 P/E 30.7× · PEG — 15% evidence | 7.1/20 RS sector -7% · RS bench -4.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 9.5 + 10.1 + 7.1 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Calumet, Inc.CLMT | 41.5/100Mixed-negative evidence64% evidence | BREAKING OUT | 9.4/35 Revenue -0.1% · PAT — · OPM change -11.7 pp 62% evidence | 3.0/25 ROCE -9.1% · OPM -16.6% 76% evidence | 10.3/20 P/E 30.3× · PEG — 15% evidence | 18.8/20 RS sector 40.5% · RS bench 42% · 1Y 189.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 3 + 10.3 + 18.8 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 42%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Perimeter Solutions, Inc.PRM | 40.4/100Thin evidence · provisional58% evidence | FADING | 10.0/35 Revenue — · PAT — · OPM change -50 pp 45% evidence | 7.5/25 ROCE -7.6% · OPM 58% 76% evidence | 9.0/20 P/E 53.3× · PEG — 15% evidence | 13.9/20 RS sector 7.8% · RS bench 10.3% · 1Y 84.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 7.5 + 9 + 13.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23DuPont de Nemours, Inc.DD | 38.9/100Mixed-negative evidence81% evidence | BASING | 22.2/35 Revenue 4% · PAT 40.7% · OPM change 5.2 pp 83% evidence | 7.5/25 ROCE 0.7% · OPM 11.1% 76% evidence | 4.3/20 P/E 45.4× · PEG 4.12 65% evidence | 4.9/20 RS sector -21.8% · RS bench -19.3% · 1Y -32.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 7.5 + 4.3 + 4.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Albemarle CorporationALB | 38.3/100Thin evidence · provisional53% evidence | ASLEEP | 20.0/35 Revenue — · PAT — · OPM change 14.5 pp 32% evidence | 9.2/25 ROCE 1.6% · OPM 16.3% 76% evidence | 9.1/20 P/E 47.9× · PEG — 15% evidence | 0.0/20 RS sector -22.9% · RS bench -21.8% · 1Y 60.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 9.2 + 9.1 + 0 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Hawkins, Inc.HWKN | 37.8/100Thin evidence · provisional58% evidence | ASLEEP | 14.8/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 12.7/25 ROCE 4.4% · OPM 8.8% 76% evidence | 9.4/20 P/E 41.9× · PEG — 15% evidence | 0.9/20 RS sector -22.8% · RS bench -20.8% · 1Y -24.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 12.7 + 9.4 + 0.9 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26LyondellBasell Industries N.V.LYB | 33.4/100Adverse evidence71% evidence | ASLEEP | 13.1/35 Revenue -9.4% · PAT -164.8% · OPM change 1.8 pp 83% evidence | 6.5/25 ROCE 0.9% · OPM 3.3% 76% evidence | 8.6/20 P/E 76.1× · PEG — 15% evidence | 5.2/20 RS sector -5.6% · RS bench -4.2% · 1Y 24.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 6.5 + 8.6 + 5.2 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27The Chemours CompanyCC | 28.8/100Adverse evidence64% evidence | ASLEEP | 12.7/35 Revenue 0.6% · PAT -3836.4% · OPM change -2 pp 62% evidence | 4.4/25 ROCE 0.5% · OPM 1.9% 76% evidence | 8.5/20 P/E 225.5× · PEG — 15% evidence | 3.2/20 RS sector -7.7% · RS bench -6.6% · 1Y 47.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 4.4 + 8.5 + 3.2 = 28.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Westlake CorporationWLK | 26.1/100Adverse evidence64% evidence | BASING | 9.8/35 Revenue -8.6% · PAT -473.1% · OPM change -5.4 pp 62% evidence | 4.7/25 ROCE -1% · OPM -6.5% 76% evidence | 9.6/20 P/E 33.6× · PEG — 15% evidence | 2.0/20 RS sector -17.5% · RS bench -16.2% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 4.7 + 9.6 + 2 = 26.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Solstice Advanced Materials, Inc.SOLS | 46.2/100Thin evidence · provisional36% evidence | ASLEEP | 12.4/35 Revenue — · PAT — · OPM change -4.5 pp 39% evidence | 15.1/25 ROCE 9.6% · OPM 16.5% 76% evidence | 8.7/20 P/E 67.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 12 weeks ahead 0% evidence |
| Exact sum: 12.4 + 15.1 + 8.7 + 10 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Cabot Corporation's stock price today?
Cabot Corporation trades at $82.0, +13.8% over the past year. The company is valued at $4.0 B. The stock sits at 64% of its 52-week range of $61–$93, +8.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 2 weeks in. — as of 5 August 2026.
What were Cabot Corporation's latest quarterly results?
Cabot Corporation reported revenue of $0.9 B and net profit of $0.1 B for the Mar 26 quarter. Revenue fell 4.3% and profit fell 20.0% year on year. Earnings per share were $1.27. The operating margin was 14.4%, 2.6 pp lower than a year earlier. — as of 5 August 2026.
What is Cabot Corporation's revenue?
Cabot Corporation reported revenue of $0.9 B in the Mar 26 quarter, −4.3% year on year. For the full FY25 fiscal year, revenue was $3.7 B (−7.0%). Over the last 4 years revenue compounded at 2.1% a year. — as of 5 August 2026.
What is Cabot Corporation's profit?
Cabot Corporation earned $0.1 B of net profit in the Mar 26 quarter, −20.0% year on year. Full-year FY25 profit was $0.4 B. The operating margin ran 14.4% in the latest quarter. — as of 5 August 2026.
What is Cabot Corporation's market cap?
Cabot Corporation's market capitalisation is $4.0 B at a stock price of $82.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Cabot Corporation pay a dividend?
Yes — Cabot Corporation declared $0.45 per share for Mar 26, and $1.80 per share across the last four reported quarters. The latest quarter is up 4.7% on the same quarter a year earlier. — as of 5 August 2026.
What is Cabot Corporation's dividend per share?
Cabot Corporation's most recently declared dividend is $0.45 per share for Mar 26, giving $1.80 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Cabot Corporation's dividend yield?
Cabot Corporation's trailing dividend yield is 2.20%: $1.80 declared per share across the last four reported quarters, against a share price of $82.0. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Cabot Corporation growing?
Not right now — Cabot Corporation's latest numbers are shrinking: latest-quarter revenue −4.3% year on year, profit −20.0%, and the margin −2.6 pp at 14.4%. The 4-year compound rates are 2.1% (revenue) and 7.0% (profit). The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is Cabot Corporation performing?
Cabot Corporation is in a confirmed uptrend, 2 weeks in. Its latest quarter's revenue fell 4.3% and profit fell 20.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Cabot Corporation in?
Topping out — profit and EPS growth have decelerated hard (profit growth +112.5% at its peak → −31.9% latest) while ROCE still reads 19.7%. The read comes from the last 12 quarters of growth (revenue growth −8.7% latest, profit growth −31.9% latest, eps growth −31.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Cabot Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 2 of stage 2), trading +8.7% versus its 200-day average and at 64% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Cabot Corporation beating the market?
Not lately — on a trailing-13-week view Cabot Corporation is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +74% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Cabot Corporation's stock price go up?
This page publishes no price forecast for Cabot Corporation. What it measures instead: the stock price is $82.0, the price is in a confirmed uptrend 2 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Cabot Corporation?
Somewhat — short interest is 6.8% of Cabot Corporation's tradable float, about 5.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Cabot Corporation have too much debt?
It is moderate — Cabot Corporation's debt-to-equity is 0.73. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Cabot Corporation's capex?
Cabot Corporation spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.3 B. — as of 5 August 2026.
What is Cabot Corporation's cash flow?
Cabot Corporation generated $0.7 B of operating cash flow in FY25 and $0.4 B of free cash flow after $0.3 B of capital spending. Reported profit that year was $0.4 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Cabot Corporation's profit real cash?
Yes — over the last 3 fiscal years, 152% of Cabot Corporation's reported profit arrived as operating cash. In FY25, operating cash was $0.7 B against reported profit of $0.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Cabot Corporation?
On the balance sheet, the Z-score reads 3.23 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Cabot Corporation in its business cycle?
Cabot Corporation's FY25 operating margin was 16.7%, against a 5-year band of 9.0%–16.7%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Cabot Corporation story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Cabot Corporation a stock worth studying right now?
This is not investment advice. The machine read: Cabot Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.